Enzyme Inhibition in Managing Cardiovascular Diseases

Shivendra      Kumar; Sunam      Saha; Arockia      Babu; Mohit      Agrawal; Kuldeep      Singh; Hema      Chaudhary; Khushboo      Lavania

doi:10.2174/0115734080275060231228093149

Abstract

Enzyme inhibition stands as a crucial strategy in tackling cardiovascular diseases (CVDs), countering their significant global impact on health. Targeting key enzymes involved in critical disease pathways has emerged as a pivotal pharmacological approach across various cardiovascular conditions. In hypertension, ACE inhibitors effectively lower blood pressure by impeding the conversion of angiotensin I to angiotensin II, promoting vasodilation and reducing cardiac workload. CAD management often involves statins, which competitively inhibit 3-hydroxy-3-methylglutarylcoenzyme A reductase, thereby lowering cholesterol levels and curbing plaque formation in coronary arteries. For heart failure, neprilysin inhibitors combined with ARBs exhibit promise by preserving beneficial peptides, supporting heart function and regulating fluid balance. Aspirin, an irreversible COX enzyme inhibitor, reduces platelet aggregation, mitigating thromboxane A2 formation and lowering the risk of clot-related complications in atherosclerosis. Managing dyslipidemia involves drugs like ezetimibe, targeting cholesterol absorption in the intestines and reducing LDL cholesterol levels. However, administering these drugs mandates careful consideration of patient-specific factors, potential side effects, and contraindications. Integrating lifestyle changes, such as a healthy diet and regular exercise remains integral to CVD management. The potential of enzyme inhibition in disrupting disease pathways and addressing key factors in CVD progression is evident. Yet, it necessitates ongoing research for refining existing therapies and developing novel inhibitors to augment cardiovascular outcomes and elevate patients' quality of life.

Keywords: Cardiovascular diseases, enzyme inhibition, angiotensin-converting enzyme (ACE) inhibitors, coronary artery disease (CAD), heart failure, neprilysin inhibitors, angiotensin receptor blockers (ARBs), platelet aggregation.

J Am Coll Cardiol Roth G.A. 76 2982 2020 10.1016/j.jacc.2020.11.010 Roth G.A.; Mensah G.A.; Johnson C.O.; Global burden of cardiovascular diseases and risk factors, 1990–2019. J Am Coll Cardiol 2020,76(25),2982-3021 Can J Cardiol Kreatsoulas C. 26 8C 2010 10.1016/S0828-282X(10)71075-8 Kreatsoulas C.; Anand S.S.; The impact of social determinants on cardiovascular disease. Can J Cardiol 2010,26,8C-13C Med J Armed Forces India Sreeniwas K.A. 76 1 2020 10.1016/j.mjafi.2019.12.005 Sreeniwas K.A.; Sinha N.; Cardiovascular disease in India: A 360 degree overview. Med J Armed Forces India 2020,76(1),1-3 In: Promoting Cardiovascular Health in the Developing World: A Critical Challenge to Achieve Global Health Washington (DC) 2010 Reducing the Burden of Cardiovascular Disease Intervention Approaches. In: Promoting Cardiovascular Health in the Developing World: A Critical Challenge to Achieve Global Health Washington (DC) 2010 Int J Environ Res Public Health Sharifi-Rad J. 17 2326 2020 10.3390/ijerph17072326 Sharifi-Rad J.; Rodrigues C.F.; Sharopov F.; Diet, lifestyle and cardiovascular diseases: Linking pathophysiology to cardioprotective effects of natural bioactive compounds. Int J Environ Res Public Health 2020,17(7),2326 Redox Biol Gianazza E. 23 101119 2019 10.1016/j.redox.2019.101119 Gianazza E.; Brioschi M.; Fernandez A.M.; Banfi C.; Lipoxidation in cardiovascular diseases. Redox Biol 2019,23,101119 Molecules Ramsay R. 22 1192 2017 10.3390/molecules22071192 Ramsay R.; Tipton K.; Assessm ent of enzyme inhibition: A review with examples from the development of monoamine oxidase and cholinesterase inhibitory drugs. Molecules 2017,22(7),1192 Int J Mol Sci de la Fuente M. 22 9181 2021 10.3390/ijms22179181 de la Fuente M.; Lombardero L.; Gómez-González A.; Enzyme therapy: Current challenges and future perspectives. Int J Mol Sci 2021,22(17),9181 Circulation Schwalm J.D. 133 742 2016 10.1161/CIRCULATIONAHA.115.008721 Schwalm J.D.; McKee M.; Huffman M.D.; Yusuf S.; Resource effective strategies to prevent and treat cardiovascular disease. Circulation 2016,133(8),742-755 Curr Enzym Inhib Singh K. 19 157 2023 10.2174/1573408019666230731113105 Singh K.; Gupta J.K.; Pathak D.; Kumar S.; The use of enzyme inhibitors in drug discovery: Current strategies and future prospects. Curr Enzym Inhib 2023,19(3),157-166 Biochemistry Tuley A. 57 3326 2018 10.1021/acs.biochem.8b00315 Tuley A.; Fast W.; The taxonomy of covalent inhibitors. Biochemistry 2018,57(24),3326-3337 Pharmaceutics Deodhar M. 12 846 2020 10.3390/pharmaceutics12090846 Deodhar M.; Al Rihani S.B.; Arwood M.J.; Mechanisms of CYP450 inhibition: Understanding drug-drug interactions due to mechanism-based inhibition in clinical practice. Pharmaceutics 2020,12(9),846 Physiology, Noncompetitive Inhibitor Delaune K.P. 2022 Delaune K.P.; Alsayouri K.; Physiology, Noncompetitive Inhibitor 2022 In: Assay Guidance Manual Strelow J. 2012 Strelow J.; Dewe W.; Iversen P.W.; In: Assay Guidance Manual 2012 Nat Rev Drug Discov Holdgate G.A. 17 115 2017 10.1038/nrd.2017.219 Holdgate G.A.; Meek T.D.; Grimley R.L.; Mechanistic enzymology in drug discovery: A fresh perspective. Nat Rev Drug Discov 2017,17,115-132 Biochim Biophys Acta Protein Struct Mol Enzymol Kotlyar A.B. 784 24 1984 10.1016/0167-4838(84)90168-7 Kotlyar A.B.; Vinogradov A.D.; Interaction of the membrane-bound succinate dehydrogenase with substrate and competitive inhibitors. Biochim Biophys Acta Protein Struct Mol Enzymol 1984,784(1),24-34 J Enzyme Inhib Med Chem Zolghadri S. 34 279 2019 10.1080/14756366.2018.1545767 Zolghadri S.; Bahrami A.; Hassan Khan M.T.; A comprehensive review on tyrosinase inhibitors. J Enzyme Inhib Med Chem 2019,34(1),279-309 J Indian Chem Soc Hajizadeh M. 19 1575 2022 10.1007/s13738-021-02416-4 Hajizadeh M.; Moosavi-Movahedi Z.; Sheibani N.; Moosavi-Movahedi A.A.; An outlook on suicide enzyme inhibition and drug design. J Indian Chem Soc 2022,19(5),1575-1592 Curr Neuropharmacol 11 315 2013 10.2174/1570159X11311030006 Coloviand#263; MB, Krstiand#263; DZ, Lazareviand#263;-Pašti TD, Bondžiand#263; AM, Vasiand#263; VM. Acetylcholinesterase inhibitors: Pharmacology and toxicology. Curr Neuropharmacol 2013,11(3),315-335 Essays Biochem Robinson P.K. 59 1 2015 10.1042/bse0590001 Robinson P.K.; Enzymes: Principles and biotechnological applications. Essays Biochem 2015,59,1-41 IntechOpen Lopina O.D. 2017 10.5772/67248 Lopina O.D.; Lopina O.D.; Enzyme Inhibitors and Activators. IntechOpen 2017 Comput Struct Biotechnol J Byun J.A. 18 3803 2020 10.1016/j.csbj.2020.10.026 Byun J.A.; VanSchouwen B.; Akimoto M.; Melacini G.; Allosteric inhibition explained through conformational ensembles sampling distinct “mixed” states. Comput Struct Biotechnol J 2020,18,3803-3818 Microbiol Mol Biol Rev Helmstaedt K. 65 404 2001 10.1128/MMBR.65.3.404-421.2001 Helmstaedt K.; Krappmann S.; Braus G.H.; Allosteric regulation of catalytic activity: Escherichia coli aspartate transcarbamoylase versus yeast chorismate mutase. Microbiol Mol Biol Rev 2001,65(3),404-421 Plant J Hartman M.D. 114 1037 2023 10.1111/tpj.16215 Hartman M.D.; Rojas B.E.; Iglesias A.A.; Figueroa C.M.; The involvement of allosteric effectors and postand#8208;translational modifications in the control of plant central carbon metabolism. Plant J 2023,114(5),1037-1058 Mol Offenbacher A.R. 25 3374 2020 10.3390/molecules25153374 Offenbacher A.R.; Holman T.R.; Fatty acid allosteric regulation of C-H activation in plant and animal lipoxygenases. Mol 2020,25,3374 ACE Inhibitors Goyal A. 2022 Goyal A.; Cusick A.S.; Thielemier B.; ACE Inhibitors 2022 Ther Clin Risk Manag Bussard R. 14 1287 2018 10.2147/TCRM.S150434 Bussard R.; Busse L.; Angiotensin I.I.; Angiotensin I.I.; A new therapeutic option for vasodilatory shock. Ther Clin Risk Manag 2018,14,1287-1298 Electrolyte Blood Press Yim H.E. 6 42 2008 10.5049/EBP.2008.6.1.42 Yim H.E.; Yoo K.H.; Renin-Angiotensin system - considerations for hypertension and kidney. Electrolyte Blood Press 2008,6(1),42-50 Am J Ther Katragadda S. 17 e11 2010 10.1097/MJT.0b013e31815addd9 Katragadda S.; Arora R.R.; Role of angiotensin-converting enzyme inhibitors in vascular modulation: beyond the hypertensive effects. Am J Ther 2010,17(1),e11-e23 Br J Pharmacol Ma T.K.W. 160 1273 2010 10.1111/j.1476-5381.2010.00750.x Ma T.K.W.; Kam K.K.H.; Yan B.P.; Lam Y.Y.; Renin–angiotensin–aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol 2010,160(6),1273-1292 World J Diabetes Chawla T. 1 141 2010 10.4239/wjd.v1.i5.141 Chawla T.; Sharma D.; Singh A.; Role of the renin angiotensin system in diabetic nephropathy. World J Diabetes 2010,1(5),141-145 Am J Cardiol Liao J.K. 96 24 2005 10.1016/j.amjcard.2005.06.009 Liao J.K.; Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 2005,96(5),24-33 Annu Rev Pharmacol Toxicol Liao J.K. 45 89 2005 10.1146/annurev.pharmtox.45.120403.095748 Liao J.K.; Laufs U.; Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005,45(1),89-118 Arch Neurol Willey J.Z. 67 1062 2010 10.1001/archneurol.2010.199 Willey J.Z.; Elkind M.S.V.; 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases. Arch Neurol 2010,67(9),1062-1067 4th edSpringer Boucher P. 2247 2015 Boucher P.; Vogel H.G.; In: Drug Discovery and Evaluation: Pharmacological Assays. 4th edSpringer 2015,2247-71 Eur Heart J Bonetti P. 24 225 2003 10.1016/S0195-668X(02)00419-0 Bonetti P.; Lerman L.O.; Napoli C.; Lerman A.; Statin effects beyond lipid lowering—are they clinically relevant? Eur Heart J 2003,24(3),225-248 Indian J Pharm Sci Aravindan R. 70 701 2008 10.4103/0250-474X.49087 Aravindan R.; Viruthagiri T.; Seenivasan A.; Subhagar S.; Microbial production and biomedical applications of lovastatin. Indian J Pharm Sci 2008,70(6),701-709 Br J Pharmacol Stalker T.J. 133 406 2001 10.1038/sj.bjp.0704070 Stalker T.J.; Lefer A.M.; Scalia R.; A new HMGand#8208;CoA reductase inhibitor, rosuvastatin, exerts antiand#8208;inflammatory effects on the microvascular endothelium: The role of mevalonic acid. Br J Pharmacol 2001,133(3),406-412 HMG-CoA Reductase Inhibitors Bansal A.B. 2022 Bansal A.B.; Cassagnol M.; HMG-CoA Reductase Inhibitors 2022 Mayo Clin Proc Karalis D.G. 84 345 2009 10.1016/S0025-6196(11)60544-2 Karalis D.G.; Intensive lowering of low-density lipoprotein cholesterol levels for primary prevention of coronary artery disease. Mayo Clin Proc 2009,84(4),345-352 Circ Res Wolf D. 124 315 2019 10.1161/CIRCRESAHA.118.313591 Wolf D.; Ley K.; Immunity and inflammation in atherosclerosis. Circ Res 2019,124(2),315-327 J Appl Physiol Muller M.D. 115 1219 2013 10.1152/japplphysiol.00885.2013 Muller M.D.; Reed A.B.; Leuenberger U.A.; Sinoway L.I.; Physiology in medicine: Peripheral arterial disease. J Appl Physiol 2013,115(9),1219-1226 Int J Mol Sci Alem M. 20 3198 2019 10.3390/ijms20133198 Alem M.; Endothelial dysfunction in chronic heart failure: Assessment, findings, significance, and potential therapeutic targets. Int J Mol Sci 2019,20(13),3198 Curr Hypertens Rep Dharmashankar K. 12 448 2010 10.1007/s11906-010-0150-2 Dharmashankar K.; Widlansky M.E.; Vascular endothelial function and hypertension: Insights and directions. Curr Hypertens Rep 2010,12(6),448-455 Int J Mol Sci Calamera G. 23 2145 2022 10.3390/ijms23042145 Calamera G.; Moltzau L.R.; Levy F.O.; Andressen K.W.; Phosphodiesterases and compartmentation of cAMP and cGMP signaling in regulation of cardiac contractility in normal and failing hearts. Int J Mol Sci 2022,23(4),2145 N Am J Med Sci Asif M. 4 499 2012 10.4103/1947-2714.102001 Asif M.; Phosphodiesterase-III inhibitors amrinone and milrinone on epilepsy and cardiovascular activities. N Am J Med Sci 2012,4(10),499-502 Int J Health Sci Res Kumar S. 7 164 2022 10.52403/ijshr.20221023 Kumar S.; Kulshreshtha D.M.; Saha S.; Contribution of phosphodiesterase-5 (PDE5) inhibitors in the various diseases. Int J Health Sci Res 2022,7(4),164-172 Int J Mol Sci Knott E. 18 696 2017 10.3390/ijms18040696 Knott E.; Assi M.; Rao S.; Ghosh M.; Pearse D.; Phosphodiesterase inhibitors as a therapeutic approach to neuroprotection and repair. Int J Mol Sci 2017,18(4),696 J Vet Intern Med Ames M.K. 33 363 2019 10.1111/jvim.15454 Ames M.K.; Atkins C.E.; Pitt B.; The reninand#8208;angiotensinand#8208;aldosterone system and its suppression. J Vet Intern Med 2019,33(2),363-382 Pharmacol Rev Arendse L.B. 71 539 2019 10.1124/pr.118.017129 Arendse L.B.; Danser A.H.J.; Poglitsch M.; Novel therapeutic approaches targeting the renin-angiotensin system and associated peptides in hypertension and heart failure. Pharmacol Rev 2019,71(4),539-570 Ther Adv Endocrinol Metab Riccioni G. 4 139 2013 10.1177/2042018813490779 Riccioni G.; The role of direct renin inhibitors in the treatment of the hypertensive diabetic patient. Ther Adv Endocrinol Metab 2013,4(5),139-145 Front Med Campbell D.J. 5 257 2018 10.3389/fmed.2018.00257 Campbell D.J.; Neprilysin inhibitors and bradykinin. Front Med 2018,5,257 Pharma-Kritik Nicolas D. 38 5 2023 10.1310/hpj5011-1025 Nicolas D.; Kerndt C.C.; Reed M.; Sacubitril-valsartan. Pharma-Kritik 2023,38,5-7 Eur J Intern Med Perrone-Filardi P. 102 8 2022 10.1016/j.ejim.2022.04.006 Perrone-Filardi P.; Paolillo S.; Agostoni P.; Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: Efficacy, mechanistic effects and practical use of sacubitril/valsartan. Eur J Intern Med 2022,102,8-16 Curr Heart Fail Rep Chamsi-Pasha M.A.R. 11 58 2014 10.1007/s11897-013-0178-0 Chamsi-Pasha M.A.R.; Shao Z.; Tang W.H.W.; Angiotensin-converting enzyme 2 as a therapeutic target for heart failure. Curr Heart Fail Rep 2014,11(1),58-63 Int J Environ Res Public Health Makrilakis K. 16 2720 2019 10.3390/ijerph16152720 Makrilakis K.; The role of DPP-4 inhibitors in the treatment algorithm of type 2 diabetes mellitus: When to select, what to expect. Int J Environ Res Public Health 2019,16(15),2720 Iran J Pharm Res Zarghi A. 10 655 2011 Zarghi A.; Arfaei S.; Selective COX-2 inhibitors: A review of their structure-activity relationships. Iran J Pharm Res 2011,10(4),655-683 Arch Med Sci Fras Z. 17 954 2021 10.5114/aoms.2020.98195 Fras Z.; Tršan J.; Banach M.; On the present and future role of Lp-PLA2 in atherosclerosis-related cardiovascular risk prediction and management. Arch Med Sci 2021,17(4),954-964 Semin Cancer Biol Block K.I. 35 S276 2015 10.1016/j.semcancer.2015.09.007 Block K.I.; Gyllenhaal C.; Lowe L.; A broad-spectrum integrative design for cancer prevention and therapy. Semin Cancer Biol 2015,35,S276 Cancers Masnikosa R 15 3653 2023 10.3390/cancers15143653 Masnikosa R; Pirić D, Post JM, et al. Disturbed plasma lipidomic profiles in females with diffuse large B-cell lymphoma: A pilot study. Cancers 2023,15,3653 Cancers Lao Y. 14 3575 2022 10.3390/cancers14153575 Lao Y.; Shen D.; Zhang W.; He R.; Jiang M.; Immune checkpoint inhibitors in cancer therapy—how to overcome drug resistance? Cancers 2022,14(15),3575 Nat Rev Cancer Vanneman M. 12 237 2012 10.1038/nrc3237 Vanneman M.; Dranoff G.; Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012,12(4),237-251 World J Gastrointest Pharmacol Ther Lin D.M. 8 162 2017 10.4292/wjgpt.v8.i3.162 Lin D.M.; Koskella B.; Lin H.C.; Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. World J Gastrointest Pharmacol Ther 2017,8(3),162-173 Nat Rev Chem Miethke M. 5 726 2021 10.1038/s41570-021-00313-1 Miethke M.; Pieroni M.; Weber T.; Towards the sustainable discovery and development of new antibiotics. Nat Rev Chem 2021,5(10),726-749 Clin Breast Cancer Britten C.D. 9 16 2009 10.3816/CBC.2009.n.003 Britten C.D.; Finn R.S.; Bosserman L.D.; A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: A dual ErbB targeted approach. Clin Breast Cancer 2009,9(1),16-22 HIV AIDS Wang Y. 7 95 2015 10.2147/HIV.S79956 Wang Y.; Lv Z.; Chu Y.; HIV protease inhibitors: A review of molecular selectivity and toxicity. HIV AIDS 2015,7,95-104 Circulation Hubers S.A. 133 1115 2016 10.1161/CIRCULATIONAHA.115.018622 Hubers S.A.; Brown N.J.; Combined angiotensin receptor antagonism and neprilysin inhibition. Circulation 2016,133(11),1115-1124 PandT Gritsenko D. 40 256 2015 Gritsenko D.; Hughes G.; Ledipasvir/Sofosbuvir (harvoni): Improving options for hepatitis C virus infection. PandT 2015,40(4),256-276 Front Endocrinol Gilbert M.P. 11 178 2020 10.3389/fendo.2020.00178 Gilbert M.P.; Pratley R.E.; GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: Review of head-to-head clinical trials. Front Endocrinol 2020,11,178 Fertil Steril Goetz L.H. 109 952 2018 10.1016/j.fertnstert.2018.05.006 Goetz L.H.; Schork N.J.; Personalized medicine: Motivation, challenges, and progress. Fertil Steril 2018,109(6),952-963 Expert Rev Precis Med Drug Dev Kronfol M.M. 2 33 2017 10.1080/23808993.2017.1284557 Kronfol M.M.; Dozmorov M.G.; Huang R.; Slattum P.W.; McClay J.L.; The role of epigenomics in personalized medicine. Expert Rev Precis Med Drug Dev 2017,2(1),33-45 Cells Condrat C.E. 9 276 2020 10.3390/cells9020276 Condrat C.E.; Thompson D.C.; Barbu M.G.; miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis. Cells 2020,9(2),276 Signal Transduct Target Ther Qiu S. 8 132 2023 10.1038/s41392-023-01399-3 Qiu S.; Cai Y.; Yao H.; Small molecule metabolites: Discovery of biomarkers and therapeutic targets. Signal Transduct Target Ther 2023,8(1),132 Nat Rev Cancer Havel J.J. 19 133 2019 10.1038/s41568-019-0116-x Havel J.J.; Chowell D.; Chan T.A.; The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer 2019,19(3),133-150 Clin Cases Miner Bone Metab Mini E. 6 17 2009 Mini E.; Nobili S.; Pharmacogenetics: Implementing personalized medicine. Clin Cases Miner Bone Metab 2009,6(1),17-24 Clin Biochem Rev Shenfield G.M. 25 203 2004 Shenfield G.M.; Genetic polymorphisms, drug metabolism and drug concentrations. Clin Biochem Rev 2004,25(4),203-206 Int J Biomed Investig Lopez D. 1 1 2018 10.31531/2581-4745.1000111 Lopez D.; Lopez D.; Pharmacogenetics: an important part of drug development with a focus on its application. Int J Biomed Investig 2018,1(2),1-16 Genomics Proteomics Bioinformatics Ahmed S. 14 298 2016 10.1016/j.gpb.2016.03.008 Ahmed S.; Zhou Z.; Zhou J.; Chen S.Q.; Pharmacogenomics of drug metabolizing enzymes and transporters: Relevance to precision medicine. Genomics Proteomics Bioinformatics 2016,14(5),298-313 Technology Krzyszczyk P 6 79 2018 10.1142/S2339547818300020 Krzyszczyk P; Acevedo A; Davidoff EJ; The growing role of precision and personalized medicine for cancer treatment. Technology 2018,6(03n04),79-100 Trends Biotechnol Ho D. 38 497 2020 10.1016/j.tibtech.2019.12.021 Ho D.; Quake S.R.; McCabe E.R.B.; Enabling technologies for personalized and precision medicine. Trends Biotechnol 2020,38(5),497-518 Clin Cases Miner Bone Metab Novelli G. 5 149 2008 Novelli G.; Ciccacci C.; Borgiani P.; Papaluca A.M.; Abadie E.; Genetic tests and genomic biomarkers: Regulation, qualification and validation. Clin Cases Miner Bone Metab 2008,5(2),149-154 Circ Res Leopold J.A. 122 1302 2018 10.1161/CIRCRESAHA.117.310782 Leopold J.A.; Loscalzo J.; Emerging role of precision medicine in cardiovascular disease. Circ Res 2018,122(9),1302-1315 Am J Cardiol Pitt B. 79 24 1997 10.1016/S0002-9149(97)00126-4 Pitt B.; The potential use of angiotensin-converting enzyme inhibitors in patients with hyperlipidemia. Am J Cardiol 1997,79(5),24-28 Br J Clin Pharmacol Gresele P. 72 634 2011 10.1111/j.1365-2125.2011.04034.x Gresele P.; Momi S.; Falcinelli E.; Antiand#8208;platelet therapy: Phosphodiesterase inhibitors. Br J Clin Pharmacol 2011,72(4),634-646 JAMA Lamas G.A. 309 1241 2013 10.1001/jama.2013.2107 Lamas G.A.; Goertz C.; Boineau R.; Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: The TACT randomized trial. JAMA 2013,309(12),1241-1250 BMC Cardiovasc Disord Tai C. 17 257 2017 10.1186/s12872-017-0686-z Tai C.; Gan T.; Zou L.; Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: A meta-analysis of randomized controlled trials. BMC Cardiovasc Disord 2017,17(1),257 N Engl J Med Yusuf S. 342 145 2000 10.1056/NEJM200001203420301 Yusuf S.; Sleight P.; Pogue J.; Bosch J.; Davies R.; Dagenais G.; Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000,342(3),145-153 Vasc Health Risk Manag Kapur N. 4 341 2008 10.2147/VHRM.S1653 Kapur N.; Musunuru K.; Clinical efficacy and safety of statins in managing cardiovascular risk. Vasc Health Risk Manag 2008,4(2),341-353 Drug Des Devel Ther Kones R. 4 383 2010 10.2147/DDDT.S10812 Kones R.; Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease – a perspective. Drug Des Devel Ther 2010,4,383-413 Lancet Gent M.A. 348 1329 1996 10.1016/S0140-6736(96)09457-3 Gent M.A.; A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996,348(9038),1329-1339 Vasc Health Risk Manag Barnett C.F. 2 411 2006 10.2147/vhrm.2006.2.4.411 Barnett C.F.; Machado R.F.; Sildenafil in the treatment of pulmonary hypertension. Vasc Health Risk Manag 2006,2(4),411-422 Prev Med Rep Thongtang N. 27 101819 2022 10.1016/j.pmedr.2022.101819 Thongtang N.; Sukmawan R.; Llanes E.J.B.; Lee Z.V.; Dyslipidemia management for primary prevention of cardiovascular events: Best in-clinic practices. Prev Med Rep 2022,27,101819 Ochsner J Azimova K. 14 616 2014 Azimova K.; San Juan Z.; Mukherjee D.; Cardiovascular safety profile of currently available diabetic drugs. Ochsner J 2014,14(4),616-632 Turk Thorac J Yilmaz I. 20 36 2019 10.5152/TurkThoracJ.2018.18014 Yilmaz I.; Angiotensin-converting enzyme inhibitors induce cough. Turk Thorac J 2019,20(1),36-42 Expert Rev Clin Immunol Selva-O’Callaghan A. 14 215 2018 10.1080/1744666X.2018.1440206 Selva-O’Callaghan A.; Alvarado-Cardenas M.; Pinal-Fernández I.; Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations. Expert Rev Clin Immunol 2018,14(3),215-224 Cureus Abubakar M. 15 e36335 2023 10.7759/cureus.36335 Abubakar M.; Raza S.; Hassan K.M.; Efficacy, safety, and role of antiplatelet drugs in the management of acute coronary syndrome: A comprehensive review of literature. Cureus 2023,15(3),e36335 PandT Huang S.A. 38 407 2013 Huang S.A.; Lie J.D.; Phosphodiesterase-5 (PDE5) inhibitors in the management of erectile dysfunction. PandT 2013,38(7),407-419 BMJ Davies M.K. 320 428 2000 10.1136/bmj.320.7232.428 Davies M.K.; Gibbs C.R.; Lip G.Y.H.; ABC of heart failure: Management: diuretics, ACE inhibitors, and nitrates. BMJ 2000,320(7232),428-431 Oxf Med Case Rep Ezad S. 2018 omx104 2018 10.1093/omcr/omx104 Ezad S.; Cheema H.; Collins N.; Statin-induced rhabdomyolysis: A complication of a commonly overlooked drug interaction. Oxf Med Case Rep 2018,2018(3),omx104 Hematology Barnes G.D. 2020 642 2020 10.1182/hematology.2020000151 Barnes G.D.; Combining antiplatelet and anticoagulant therapy in cardiovascular disease. Hematology 2020,2020(1),642-648 Iran J Pharm Res IJPR Talebi M.M. 17 159 2018 Talebi M.M.; Sefidani Forough A.; Riazi Esfahani P.; Eskandari R.; Haghgoo R.; Fahimi F.; Medication interaction and physicians’ compliance assessment through medication reconciliation forms in a university affiliated hospital. Iran J Pharm Res IJPR 2018,17,159 Ther Clin Risk Manag Machaj F. 15 147 2019 10.2147/TCRM.S179302 Machaj F.; Dembowska E.; Rosik J.; Szostak B.; Mazurek-Mochol M.; Pawlik A.; New therapies for the treatment of heart failure: A summary of recent accomplishments. Ther Clin Risk Manag 2019,15,147-155 Preprints Singh K. 2022050290 2022 10.20944/preprints202205.0290.v1 Singh K.; Gupta J.K.; Kumar S.; Singh K.; Meenakshi K.; Kumar K.; PCSK9 inhibitors: Pharmacology and therapeutic potential. Preprints 2022,2022050290 Cells Bajan S. 9 137 2020 10.3390/cells9010137 Bajan S.; Hutvagner G.; RNA-based therapeutics: From antisense oligonucleotides to miRNAs. Cells 2020,9(1),137 Pharmaceuticals Delbaere Q. 16 78 2023 10.3390/ph16010078 Delbaere Q.; Chapet N.; Huet F.; Anti-inflammatory drug candidates for prevention and treatment of cardiovascular diseases. Pharmaceuticals 2023,16(1),78 Int J Mol Sci Jourdi G. 22 13079 2021 10.3390/ijms222313079 Jourdi G.; Lordkipanidzé M.; Philippe A.; Bachelot-Loza C.; Gaussem P.; Current and novel antiplatelet therapies for the treatment of cardiovascular diseases. Int J Mol Sci 2021,22(23),13079 World J Cardiol Napoli C. 8 211 2016 10.4330/wjc.v8.i2.211 Napoli C.; Grimaldi V.; De Pascale M.R.; Sommese L.; Infante T.; Soricelli A.; Novel epigenetic-based therapies useful in cardiovascular medicine. World J Cardiol 2016,8(2),211-219 Microb Biotechnol Xu H. 13 637 2020 10.1111/1751-7915.13524 Xu H.; Wang X.; Feng W.; The gut microbiota and its interactions with cardiovascular disease. Microb Biotechnol 2020,13(3),637-656 Korean Circ J Lee M.S. 42 583 2012 10.4070/kcj.2012.42.9.583 Lee M.S.; Flammer A.J.; Lerman L.O.; Lerman A.; Personalized medicine in cardiovascular diseases. Korean Circ J 2012,42(9),583-591 Int J Mol Sci Kandaswamy E. 19 424 2018 10.3390/ijms19020424 Kandaswamy E.; Zuo L.; Recent advances in treatment of coronary artery disease: Role of science and technology. Int J Mol Sci 2018,19(2),424 Nat Rev Mater Manzari M.T. 6 351 2021 10.1038/s41578-020-00269-6 Manzari M.T.; Shamay Y.; Kiguchi H.; Rosen N.; Scaltriti M.; Heller D.A.; Targeted drug delivery strategies for precision medicines. Nat Rev Mater 2021,6(4),351-370 J Clin Hypertens Izzo J.L. 13 667 2011 10.1111/j.1751-7176.2011.00508.x Izzo J.L.; Weir M.R.; Angiotensin-converting enzyme inhibitors. J Clin Hypertens 2011,13(9),667-675 J Crit Care Med 2 6 2016 10.1515/jccm-2015-0021 Mand#259;rginean A, Band#259;nescu C, Scridon A, Dobreanu M. Anti-platelet therapy resistance – concept, mechanisms and platelet function tests in intensive care facilities. J Crit Care Med 2016,2(1),6-15 Genes Dis Anand U. 10 1367 2023 10.1016/j.gendis.2022.02.007 Anand U.; Dey A.; Chandel A.K.S.; Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis 2023,10(4),1367-1401 BMJ Vrijens B. 336 1114 2008 10.1136/bmj.39553.670231.25 Vrijens B.; Vincze G.; Kristanto P.; Urquhart J.; Burnier M.; Adherence to prescribed antihypertensive drug treatments: Longitudinal study of electronically compiled dosing histories. BMJ 2008,336(7653),1114-1117 J Res Med Sci Palleria C. 18 601 2013 Palleria C.; Di Paolo A.; Giofrè C.; Pharmacokinetic drug-drug interaction and their implication in clinical management. J Res Med Sci 2013,18(7),601-610 Lancet Glob Health Kruk M.E. 6 e1196 2018 10.1016/S2214-109X(18)30386-3 Kruk M.E.; Gage A.D.; Arsenault C.; High-quality health systems in the Sustainable Development Goals era: Time for a revolution. Lancet Glob Health 2018,6(11),e1196-e1252 J Med Ethics McHenry L. 32 405 2006 10.1136/jme.2005.013185 McHenry L.; Ethical issues in psychopharmacology. J Med Ethics 2006,32(7),405-410 World Psychiatry Stroup T.S. 17 341 2018 10.1002/wps.20567 Stroup T.S.; Gray N.; Management of common adverse effects of antipsychotic medications. World Psychiatry 2018,17(3),341-356

Rights & Permissions Print Cite

Article Metrics

37

2

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/0115734080275060231228093149	Print ISSN 1573-4080
Publisher Name Bentham Science Publisher	Online ISSN 1875-6662

Current Enzyme Inhibition

Enzyme Inhibition in Managing Cardiovascular Diseases

Abstract

Graphical Abstract

Current Enzyme Inhibition

Enzyme Inhibition in Managing Cardiovascular Diseases

Abstract

Graphical Abstract

Related Journals

Related Books

Related Articles